Professor Tony S.K. Mok is the Li Shu Fan Medical Foundation endowed professor and chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. He received his medical degree from the University of Alberta, Canada and then subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Toronto, Canada. After working as a community oncologist in Toronto, Canada, he returned to Hong Kong to pursue an academic career.

Professor Mok’s main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He was the principal investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has also led and co-led multiple international Phase III studies. He dedicates his work on precision medicine for lung cancer by also engaging in clinical research on oncogene driven lung cancer and immunotherapy. His work has been adopted by multiple international guidelines, including NCCN, AMP/IASLC/CAP, ASCO, and ESMO. He also contributes to the development of clinical research infra-structure in China and Asia. Professor Mok cofounded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group, and Asia Thoracic Oncology Research Group.

Professor Mok has contributed to over 260 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet, Nature Medicine, and Journal of Clinical Oncology, and has published multiple editorials and textbooks. He served as an associate editor for thoracic oncology for the Journal of Clinical Oncology and other international journals. Professor Mok is the past president and past treasurer of the International Association for the Study of Lung Cancer (IASLC) and is active in international education activity. His work has been recognized by numerous awards.